Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion

Metabolism: Clinical and Experimental

Volumn 52, Issue 11, 2003, Pages 1496-1500

  Cheung, Peter ^a   Yang, Gangyi ^a   Boden, Guenther ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IIIB; PHOSPHODIESTERASE INHIBITOR; RNA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELECTIVITY; FATTY ACID BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPOLYSIS; LIVER; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

EID: 0345375262     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00271-3     Document Type: Article

References (27)

1. Baim DS, McDowell AV, Cherniles J, et al.: Evaluation of a new bipyridine inotropic agent - Milrinone - In patients with severe congestive heart failure. N Engl J Med 309:748-756, 1983
2. DiBianco R, Shabetani R, Kostuk W, et al: A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320:677-683, 1989
3. Reinhardt RR, Chin E, Zhou J, et al: Distinctive anatomical patterns of gene expression for two cGMP-inhibited nucleotide phosphodiesterase sub-families. J Clin Invest 95:1528-1538, 1995
4. Hagstrom-Toft E, Bolinder J, Eriksson S, et al: Role of phosphodiesterase III in the antilipolytic effect of insulin in vivo. Diabetes 44:1170-1175, 1995
5. Degerman E, Landstrom TR, Holst LS, et al: A role for phosphodiesterase 3B in the antilipolytic action of insulin, in LeRoit D, Taylor SI, Olefsky JM (eds): Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 284-291
6. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
7. Boden G, Cheung P, Stein TP, et al: FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol 283:E12-E19, 2002
8. Parker JC, Van Volkenburg MA, Nardone NA, et al: Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem Biochem Res Commun 236:665-669, 1997
9. Cases JA, Gabriely H, Ma XH, et al: Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes 50:348-352, 2001
10. Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84:892-899, 1989
11. Shah P, Vella A, Basu A, et al: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059, 2000
12. Wolfe RR: Tracers in metabolic research, in Radioisotope and Stable Isotope/Mass Spectrometry Methods. New York, NY, Liss, 1984, p 261
13. Steele R, Wall JS, DeBodo RC, et al: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24, 1956
14. Smith D, Rossetti L, Ferrannini E, et al: In vivo glucose metabolism in the awake rat: Tracer and insulin clamp studies. Metabolism 36:1167-1174, 1987
15. Physicians Desk Reference. Thomson Healthcare 55th Edition. Montvale, NJ, Medical Economics Co, 2001, p 2760
16. Nestel PG, Whyte HM: Plasma free fatty acid and triglyceride turnover in obesity. Metabolism 17:1122-1128, 1968
17. Elks ML, Manganiello VC, Vaughan M: Hormone-sensitive particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes. J Biol Chem 258:8582-8587, 1983
18. Eriksson H, Ridderstrale M, Degerman E, et al: Evidence for the key role of the adipocyte cGMP-inhibited cAMP phosphodiesterase in the antilipolytic action of insulin. Biochim Biophys Acta 1266:101-107, 1995
19. Beebe SJ, Redmon JB, Blackmore PF, et al: Discriminative insulin antagonism of stimulatory effects of various cAMP analogs on adipocyte lipolysis and hepatocytes glycogenolysis. J Biol Chem 260:15781-15788, 1985
20. Parker JC, Van Volkenburg MA, Nardon NA, et al: Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem Biochem Res Commun 236:665-669, 1997
21. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748, 1995
22. Zhao AZ, Zhao H, Teague J, et al: Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94:3223-3228, 1997
23. Zhao AZ, Bronfeldt KE, Beavo JA: Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102:869-873, 1998
24. Parker JC, VanVolkenburg MA, Ketchum RJ, et al: Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: Contributions of types III and IV to the modulation of insulin secretion. Biochem Biophys Res Commun 217:916-923, 1995
25. Leibowitz MD, Biswas C, Brady EJ, et al: A novel insulin secretagogue is a phosphodiesterase inhibitor. Diabetes 44:67-74, 1995
26. Ahmad M, Abdel-Wahab YHA, Tate R, et al: Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11. Br J Pharmacol 129:1228-1234, 2000
27. Shafiee-Nick N, Pyne NJ, Furman BL: Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br J Pharmacol 115:1486-1492, 1995